Supplement
Retatrutide
Triple agonist: the pipeline's biggest number.
Retatrutide is an investigational triple agonist (GIP, GLP-1, glucagon). We grade Retatrutide B on evidence and D for worth-it at about not commercially available as an approved product per month.
Evidence
Worth it
Typical cost: not commercially available as an approved product/month
What it does
Retatrutide is an investigational triple agonist (GIP, GLP-1, glucagon). A Phase 2 trial published in NEJM (2023) reported about 24% mean weight loss at 48 weeks on the 12 mg dose. Not approved; Phase 3 trials are ongoing.
What the research says
Weight loss in Phase 2
Evidence: moderate. NEJM 2023 Phase 2: ~24% at 48 weeks. Phase 2 only; no approval, no Phase 3 readout yet.
DRAFT: one strong Phase 2, but Phase 2 is not approval.
Is it worth it?
DRAFT: not available as an approved product at any price.
Typical cost
not commercially available as an approved product/month
Common form, not a brand recommendation
Dosage contextno established dose
No approved dose. Phase 2 tested up to 12 mg weekly; trial doses, not recommendations.
Safety notes
INVESTIGATIONAL: GI effects as with the class; long-term profile unknown until Phase 3 completes. Not obtainable through legitimate medical channels. Talk to your doctor. This page is information, not medical advice.
Longevity Lab Report
Retatrutide news, graded when it happens.
New studies, dose debates, and expert shifts on retatrutide, in one email a week. Free.
Changelog
Last updated 2026-10-15
- 2026-10-15|Batch 3 entry, DRAFT. Grades provisional; expert positions unsourced unless noted.